Selective internal radiation therapy for neuroendocrine tumours that have metastasised to the liver (HTG720)Product type:GuidanceProgramme:HealthTech guidancePublished: 16 May 2024
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 August 2018
Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease (TA449)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 June 2017